Transparency Market Research in its new report titled, “Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the oncolytic virus immunotherapy market. The TMR report anticipates that the rise in the number of cancer cases across the globe will drive the oncolytic virus immunotherapy market during the forecast period i.e, 2018-2026. Prevalence of diseases such as cancer has increased due to rising geriatric population and changing lifestyle in developing economies. The above-mentioned factors are anticipated to drive the demand for better diagnosis and prevention of cancer in the near future. This, in turn, would offer growth opportunities to companies operating in the oncolytic virus immunotherapy market in the next few years, says the report.
According to the report, high investments in research and development of alternate therapies by public as well as private organizations for cancer treatment with high potency and low toxicity compared to other conventional and chemotherapy is also anticipated to drive the global oncolytic virus immunotherapy market during the forecast period. However, high cost of treatments is one of the major concerns for patients as well as payers. Moreover, lack of awareness about skin disorders in developing countries is expected to hamper the global oncolytic virus immunotherapy market during the forecast period. Also, some of the wild type viruses considered potential candidate for oncolytic virus immunotherapy include reovirus, senecavirus, vaccinia virus, vesicular stomatitis virus, poliovirus, rigvir, and others. There are number of research studies undergoing in different phases of clinical trial to explore the potential of these viruses in cancer immunotherapy.
On a geographical perspective, the oncolytic virus immunotherapy market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to account for the largest share of the market due to high adoption of novel potential therapies, high expenditure on health care R&D, and introduction of technologically progressive services in the region. The market in Asia Pacific is expected to expand at a high CAGR owing to adoption of advanced treatment options increasing in developing regions, thereby providing growth opportunities to the global market. The market in developing countries in Asia Pacific is expected to expand at a rapid growth rate during the forecast period.
Some of the major factors driving the market are rapid development of health care infrastructure, rise in affordability, increase in per capita income, and increase in emphasis on research & development in the health care sector. One of the most important driving factors for the developing countries such as India and China is the availability of superior treatment facilities at quite lower prices than countries in the West. This attracts patients from the U.S. and Europe, where cancer is highly prevalent, toward these countries. Moreover, growing medical tourism in developing economies is anticipated to open new avenues for the cancer treatment market in these countries in the next few years.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]